Balance Sheet Crinetics Pharmaceuticals, Inc.

Equities

CRNX

US22663K1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:30:00 11/02/2026 am IST			5-day change	1st Jan Change
47.61 ^USD	+3.48%		-3.53%	+2.28%

26/01	Crinetics Pharmaceuticals, Inc. Approves Change in Title and Responsibilities for Jeff Knight, from Chief Operating Officer to Chief Development and Operating Officer, Effective January 2, 2026	CI
23/01	Crinetics initiates phase 2/3 pediatric trial evaluating atumelnant in congenital adrenal hyperplasia (CAH)	RE

be78828a0b57593.zo9Kbbih9yM_vaPwnmwOwftEVRHASHlVBNwoWXYtV6o.n98CK9TZnmp369ud3yM3qokyAXvtGxsPR5RDaRp7EueaungOi5WUFHvk5g

Published financial data: CRINETICS PHARMACEUTICALS, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2020	2021	2022	2023	2024
Revenues	71T	10.78L	47.37L	40.13L	10.39L
Total Revenues	71T	10.78L	47.37L	40.13L	10.39L
Cost of Goods Sold, Total	5.7Cr	8.43Cr	13Cr	17Cr	24Cr
Gross Profit	-5.69Cr	-8.32Cr	-13Cr	-16Cr	-24Cr
Selling General & Admin Expenses, Total	1.8Cr	2.45Cr	4.24Cr	5.81Cr	9.97Cr
Other Operating Expenses, Total	1.8Cr	2.45Cr	4.24Cr	5.81Cr	9.97Cr
Operating Income	-7.5Cr	-11Cr	-17Cr	-22Cr	-34Cr
Interest Expense, Total	-	-	-	-	-
Interest And Investment Income	10L	2L	43.17L	1.34Cr	4.14Cr
Net Interest Expenses	10L	2L	43.17L	1.34Cr	4.14Cr
Income (Loss) On Equity Invest.	-	-	-10.1L	-51.98L	-5L
Currency Exchange Gains (Loss)	-2L	-1L	28T	-23T	-
Other Non Operating Income (Expenses)	3L	11T	6L	-1L	-5L
EBT, Excl. Unusual Items	-7.38Cr	-11Cr	-16Cr	-21Cr	-30Cr
EBT, Incl. Unusual Items	-7.38Cr	-11Cr	-16Cr	-21Cr	-30Cr
Earnings From Continuing Operations	-7.38Cr	-11Cr	-16Cr	-21Cr	-30Cr
Net Income to Company	-7.38Cr	-11Cr	-16Cr	-21Cr	-30Cr
Net Income - (IS)	-7.38Cr	-11Cr	-16Cr	-21Cr	-30Cr
Net Income to Common Incl Extra Items	-7.38Cr	-11Cr	-16Cr	-21Cr	-30Cr
Net Income to Common Excl. Extra Items	-7.38Cr	-11Cr	-16Cr	-21Cr	-30Cr
Per Share Items
Net EPS - Basic	-2.42	-2.8	-3.15	-3.69	-3.69
Basic EPS - Continuing Operations	-2.42	-2.8	-3.15	-3.69	-3.69
Basic Weighted Average Shares Outstanding	3.04Cr	3.84Cr	5.2Cr	5.81Cr	8.08Cr
Net EPS - Diluted	-2.42	-2.8	-3.15	-3.69	-3.69
Diluted EPS - Continuing Operations	-2.42	-2.8	-3.15	-3.69	-3.69
Diluted Weighted Average Shares Outstanding	3.04Cr	3.84Cr	5.2Cr	5.81Cr	8.08Cr
Normalized Basic EPS	-1.52	-1.75	-1.97	-2.31	-2.31
Normalized Diluted EPS	-1.52	-1.75	-1.97	-2.31	-2.31
Supplemental Items
EBITDA	-7.4Cr	-11Cr	-17Cr	-22Cr	-34Cr
EBITA	-7.5Cr	-11Cr	-17Cr	-22Cr	-34Cr
EBIT	-7.5Cr	-11Cr	-17Cr	-22Cr	-34Cr
EBITDAR	-7.3Cr	-11Cr	-17Cr	-22Cr	-33Cr
Total Revenues (As Reported)	-	10.78L	47.37L	-	-
Normalized Net Income	-4.61Cr	-6.73Cr	-10Cr	-13Cr	-19Cr
Interest on Long-Term Debt	-	-	-	-	-
Supplemental Operating Expense Items
General and Administrative Expenses	1.8Cr	2.45Cr	4.24Cr	5.81Cr	9.97Cr
Research And Development Expense From Footnotes	5.76Cr	8.46Cr	13Cr	17Cr	24Cr
Net Rental Expense, Total	10L	10L	10L	33L	85L
Stock-Based Comp., COGS (Total)	52.18L	96.54L	1.51Cr	2.26Cr	4.07Cr
Stock-Based Comp., G&A Exp. (Total)	52.09L	76.98L	1.32Cr	1.83Cr	2.87Cr
Total Stock-Based Compensation	1.04Cr	1.74Cr	2.83Cr	4.09Cr	6.94Cr

Fiscal Period: December	2020	2021	2022	2023	2024
Assets
Cash And Equivalents	9.31Cr	20Cr	3.27Cr	5.49Cr	26Cr
Short Term Investments	7.78Cr	13Cr	30Cr	50Cr	108.95Cr
Total Cash And Short Term Investments	17Cr	33Cr	33Cr	56Cr	135.41Cr
Other Receivables	18.33L	14.76L	22.9L	92.61L	84.7L
Total Receivables	18.33L	14.76L	22.9L	92.61L	84.7L
Prepaid Expenses	17.17L	18L	35.06L	34.31L	1.04Cr
Restricted Cash	-	-	-	-	5L
Other Current Assets, Total	30.62L	77.37L	49.63L	29.06L	19.21L
Total Current Assets	18Cr	34Cr	35Cr	57Cr	137.54Cr
Gross Property Plant And Equipment	79.71L	81.97L	90.7L	6.25Cr	6.33Cr
Accumulated Depreciation	-25.58L	-34.8L	-40.84L	-50.68L	-77.32L
Net Property Plant And Equipment	54.13L	47.17L	49.86L	5.74Cr	5.56Cr
Long-term Investments	-	10.1L	-	24.7L	20L
Other Long-Term Assets, Total	5L	6L	20.06L	13L	16.29L
Total Assets	18Cr	35Cr	35Cr	64Cr	143.46Cr
Liabilities
Accounts Payable, Total	34.88L	42.68L	68.83L	65.48L	58.53L
Accrued Expenses, Total	61.66L	1.08Cr	1.75Cr	2.73Cr	4.45Cr
Current Portion of Long-Term Debt	-	-	-	-	-
Current Portion of Leases	8L	9L	10.51L	41.73L	71.52L
Unearned Revenue Current, Total	-	-	22.4L	20.56L	21.76L
Other Current Liabilities	-	-	-	38.16L	10T
Total Current Liabilities	1.05Cr	1.6Cr	2.77Cr	4.39Cr	5.97Cr
Long-Term Debt	-	-	-	-	-
Long-Term Leases	40.14L	30.74L	20.24L	4.76Cr	4.46Cr
Unearned Revenue Non Current	-	-	61.01L	47.5L	47.04L
Other Non Current Liabilities	23T	2T	-	-	8L
Total Liabilities	1.45Cr	1.91Cr	3.58Cr	9.62Cr	11Cr
Preferred Stock Convertible	-	-	-	-	-
Total Preferred Equity	-	-	-	-	-
Common Stock, Total	34Cr	61Cr	76Cr	119.18Cr	227.6Cr
Additional Paid In Capital	-	-	-	-	-
Retained Earnings	-17Cr	-28Cr	-44Cr	-65Cr	-95Cr
Comprehensive Income and Other	25T	-4L	-39.31L	10L	10L
Total Common Equity	17Cr	33Cr	32Cr	54Cr	132.48Cr
Total Equity	17Cr	33Cr	32Cr	54Cr	132.48Cr
Total Liabilities And Equity	18Cr	35Cr	35Cr	64Cr	143.46Cr
Supplemental Items
ECS Total Shares Outstanding on Filing Date	3.3Cr	4.78Cr	5.39Cr	6.96Cr	9.3Cr
ECS Total Common Shares Outstanding	3.3Cr	4.76Cr	5.39Cr	6.82Cr	9.29Cr
Book Value / Share	5.12	6.97	5.87	7.91	14.26
Tangible Book Value	17Cr	33Cr	32Cr	54Cr	132.48Cr
Tangible Book Value Per Share	5.12	6.97	5.87	7.91	14.26
Total Debt	48.49L	40.13L	30.75L	5.17Cr	5.17Cr
Net Debt	-17Cr	-33Cr	-33Cr	-51Cr	-130.23Cr
Debt Equivalent Oper. Leases	80L	80L	80L	2.64Cr	6.8Cr
Equity Method Investments, Total	-	10.1L	-	5L	-
Account Code - Inventory Valuation	3	3	3	3	3
Machinery, Total	22.45L	27.89L	40.68L	61.12L	79L
Full Time Employees	93	143	210	290	437
Part Time Employees	-	-	-	-	-

Fiscal Period: December	2020	2021	2022	2023	2024
Net Income	-7.38Cr	-11Cr	-16Cr	-21Cr	-30Cr
Depreciation & Amortization - CF	9L	9L	10L	10.98L	27.85L
Depreciation & Amortization, Total	9L	9L	10L	10.98L	27.85L
(Gain) Loss From Sale Of Asset	-	-	-	6T	51T
(Gain) Loss on Sale of Investments - (CF)	-2L	4L	34T	-62.71L	-1.49Cr
(Income) Loss On Equity Investments - (CF)	-	-	10.1L	51.98L	5L
Stock-Based Compensation (CF)	1.04Cr	1.74Cr	2.83Cr	4.09Cr	6.94Cr
Other Operating Activities, Total	3L	-7L	-2L	-8L	30.42L
Change In Accounts Payable	27.23L	62.93L	1.1Cr	1.46Cr	1.75Cr
Change in Unearned Revenues	-	-	83.41L	-15.35L	74T
Change in Other Net Operating Assets	-23.47L	-51.97L	-7L	-50.69L	-59.8L
Cash from Operations	-6.2Cr	-8.86Cr	-12Cr	-17Cr	-23Cr
Capital Expenditure	-2L	-4L	-16.56L	-46.88L	-38.44L
Investment in Marketable and Equity Securities, Total	4L	-5.6Cr	-17Cr	-20Cr	-57Cr
Cash from Investing	2L	-5.65Cr	-17Cr	-20Cr	-57Cr
Long-Term Debt Repaid, Total	-	-	-	-	-
Total Debt Repaid	-	-	-	-	-
Issuance of Common Stock	11Cr	25Cr	13Cr	41Cr	105.99Cr
Repurchase of Common Stock	-	-	-	-	-
Issuance of Preferred Stock	-	-	-	-	-
Other Financing Activities, Total	-	-	-78L	-2.27Cr	-4.94Cr
Cash from Financing	11Cr	25Cr	12Cr	39Cr	101.04Cr
Net Change in Cash	5.28Cr	11Cr	-17Cr	2.22Cr	21Cr
Supplemental Items
Cash Interest Paid	-	-	-	-	-
Levered Free Cash Flow	-3.53Cr	-4.85Cr	-6.55Cr	-9.35Cr	-14Cr
Unlevered Free Cash Flow	-3.53Cr	-4.85Cr	-6.55Cr	-9.35Cr	-14Cr
Change In Net Working Capital	-4L	-10.01L	-1.19Cr	-82.58L	-70.42L
Net Debt Issued / Repaid	-	-	-	-	-

Fiscal Period: December	2020	2021	2022	2023	2024
Profitability
Return on Assets	-29.85	-25.19	-29.84	-28.18	-20.46
Return on Total Capital	-31.6	-26.41	-32.02	-30.57	-21.53
Return On Equity %	-51.61	-42.98	-50.57	-50.16	-32.02
Return on Common Equity	-51.61	-42.98	-50.57	-50.16	-32.02
Margin Analysis
Gross Profit Margin %	-80.18T	-7.72T	-2.65T	-4.1T	-23.01T
SG&A Margin	25.39T	2.28T	894.95	1.45T	9.6T
EBITDA Margin %	-1L	-9.91T	-3.52T	-5.52T	-32.35T
EBITA Margin %	-1L	-9.99T	-3.54T	-5.55T	-32.61T
EBIT Margin %	-1L	-9.99T	-3.54T	-5.55T	-32.61T
Income From Continuing Operations Margin %	-1L	-9.99T	-3.46T	-5.35T	-28.72T
Net Income Margin %	-1L	-9.99T	-3.46T	-5.35T	-28.72T
Net Avail. For Common Margin %	-1L	-9.99T	-3.46T	-5.35T	-28.72T
Normalized Net Income Margin	-64.98T	-6.24T	-2.16T	-3.34T	-17.95T
Levered Free Cash Flow Margin	-49.7T	-4.5T	-1.38T	-2.33T	-13.13T
Unlevered Free Cash Flow Margin	-49.7T	-4.5T	-1.38T	-2.33T	-13.13T
Asset Turnover
Asset Turnover	0	0	0.01	0.01	0
Fixed Assets Turnover	0.01	0.21	0.98	0.13	0.02
Short Term Liquidity
Current Ratio	16.92	21.55	12.45	13.07	23.04
Quick Ratio	16.47	20.96	12.15	12.92	22.83
Operating Cash Flow to Current Liabilities	-5.91	-5.54	-4.16	-3.78	-3.79
Average Days Payable Outstanding	19.86	16.8	14.44	14.54	9.45
Long Term Solvency
Total Debt/Equity	2.87	1.21	0.97	9.6	3.9
Total Debt / Total Capital	2.79	1.19	0.96	8.76	3.76
LT Debt/Equity	2.38	0.93	0.64	8.82	3.36
Long-Term Debt / Total Capital	2.31	0.91	0.63	8.05	3.24
Total Liabilities / Total Assets	7.92	5.43	10.18	15.15	7.65
EBIT / Interest Expense	-	-	-	-	-
EBITDA / Interest Expense	-	-	-	-	-
(EBITDA - Capex) / Interest Expense	-	-	-	-	-
Total Debt / EBITDA	-0.07	-0.04	-0.02	-0.24	-0.16
Net Debt / EBITDA	2.27	3.12	2	2.32	3.98
Total Debt / (EBITDA - Capex)	-0.07	-0.04	-0.02	-0.23	-0.16
Net Debt / (EBITDA - Capex)	2.27	3.1	1.98	2.27	3.93
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-94.05	1.42T	339.42	-15.28	-74.11
Gross Profit, 1 Yr. Growth %	41.21	46.11	50.87	31.1	45.35
EBITDA, 1 Yr. Growth %	39.78	44.29	56.3	32.72	51.72
EBITA, 1 Yr. Growth %	39.24	43.69	55.88	32.6	52.22
EBIT, 1 Yr. Growth %	39.24	43.69	55.88	32.6	52.22
Earnings From Cont. Operations, 1 Yr. Growth %	46.39	45.83	52.28	30.88	39.1
Net Income, 1 Yr. Growth %	46.39	45.83	52.28	30.88	39.1
Normalized Net Income, 1 Yr. Growth %	46.39	45.83	52.28	30.88	39.1
Diluted EPS Before Extra, 1 Yr. Growth %	16.23	15.52	12.6	17.15	-0.01
Net Property, Plant and Equip., 1 Yr. Growth %	-16.16	-12.86	5.7	1.05T	-3.23
Total Assets, 1 Yr. Growth %	40.7	91.35	0.33	80.41	125.79
Tangible Book Value, 1 Yr. Growth %	44.2	96.51	-4.7	70.43	145.74
Common Equity, 1 Yr. Growth %	44.2	96.51	-4.7	70.43	145.74
Cash From Operations, 1 Yr. Growth %	33.73	42.82	30.05	44.36	35.88
Capital Expenditures, 1 Yr. Growth %	-62.2	134.41	279.82	183.09	-18
Levered Free Cash Flow, 1 Yr. Growth %	20	37.39	35.04	42.87	45.86
Unlevered Free Cash Flow, 1 Yr. Growth %	20	37.39	35.04	42.87	45.86
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	-82.9	-4.94	716.81	92.94	-53.17
Gross Profit, 2 Yr. CAGR %	60.67	43.64	48.47	40.64	38.04
EBITDA, 2 Yr. CAGR %	61.88	42.01	50.17	44.03	41.9
EBITA, 2 Yr. CAGR %	61.58	41.45	49.66	43.77	42.07
EBIT, 2 Yr. CAGR %	61.58	41.45	49.66	43.77	42.07
Earnings From Cont. Operations, 2 Yr. CAGR %	64.99	46.11	49.02	41.17	34.92
Net Income, 2 Yr. CAGR %	64.99	46.11	49.02	41.17	34.92
Normalized Net Income, 2 Yr. CAGR %	64.99	46.11	49.02	41.17	34.92
Diluted EPS Before Extra, 2 Yr. CAGR %	4.19	15.88	14.05	14.85	8.23
Net Property, Plant and Equip., 2 Yr. CAGR %	13.1	-14.52	-4.03	248.93	233.86
Total Assets, 2 Yr. CAGR %	3.45	64.08	38.56	34.54	101.83
Tangible Book Value, 2 Yr. CAGR %	2.68	68.34	36.85	27.44	104.65
Common Equity, 2 Yr. CAGR %	2.68	68.34	36.85	27.44	104.65
Cash From Operations, 2 Yr. CAGR %	78.54	38.2	36.28	37.01	40.05
Capital Expenditures, 2 Yr. CAGR %	-58.09	-5.86	198.38	227.91	52.36
Levered Free Cash Flow, 2 Yr. CAGR %	78.95	28.4	36.21	38.9	47.73
Unlevered Free Cash Flow, 2 Yr. CAGR %	78.95	28.4	36.21	38.9	47.73
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	-67.38	-23.71	58.35	283.77	-1.22
Gross Profit, 3 Yr. CAGR %	99.33	55.67	46.01	42.44	42.19
EBITDA, 3 Yr. CAGR %	101.85	55.79	46.63	44.12	46.55
EBITA, 3 Yr. CAGR %	101.75	55.38	46.1	43.74	46.53
EBIT, 3 Yr. CAGR %	101.75	55.38	46.1	43.74	46.53
Earnings From Cont. Operations, 3 Yr. CAGR %	100.5	58.34	48.14	42.71	40.48
Net Income, 3 Yr. CAGR %	100.5	58.34	48.14	42.71	40.48
Normalized Net Income, 3 Yr. CAGR %	100.5	58.34	48.14	42.71	40.48
Diluted EPS Before Extra, 3 Yr. CAGR %	-28.67	7.84	14.77	15.08	9.67
Net Property, Plant and Equip., 3 Yr. CAGR %	138.3	3.68	-8.25	119.74	127.55
Total Assets, 3 Yr. CAGR %	127.41	26.99	39.27	51.3	59.88
Tangible Book Value, 3 Yr. CAGR %	124.04	27.48	39.26	47.23	58.62
Common Equity, 3 Yr. CAGR %	124.04	27.48	39.26	47.23	58.62
Cash From Operations, 3 Yr. CAGR %	87.04	65.74	35.43	38.92	36.63
Capital Expenditures, 3 Yr. CAGR %	-15.11	-25.61	49.86	193.2	106.59
Levered Free Cash Flow, 3 Yr. CAGR %	77.46	63.86	30.57	38.39	41.18
Unlevered Free Cash Flow, 3 Yr. CAGR %	77.46	63.86	30.57	38.39	41.18
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	-	12.85	18.29	10.57	-2.73
Gross Profit, 5 Yr. CAGR %	-	79.12	77.17	49.47	42.77
EBITDA, 5 Yr. CAGR %	-	78.14	79.33	50.98	44.72
EBITA, 5 Yr. CAGR %	-	77.9	79.03	50.63	44.48
EBIT, 5 Yr. CAGR %	-	77.9	79.03	50.63	44.48
Earnings From Cont. Operations, 5 Yr. CAGR %	-	78.03	78.06	51.24	42.7
Net Income, 5 Yr. CAGR %	-	78.03	78.06	51.24	42.7
Normalized Net Income, 5 Yr. CAGR %	-	78.03	78.06	51.24	42.7
Diluted EPS Before Extra, 5 Yr. CAGR %	-	-14	-13.94	10.59	12.11
Net Property, Plant and Equip., 5 Yr. CAGR %	-	83.94	65.63	68.47	53.81
Total Assets, 5 Yr. CAGR %	-	94.54	86.53	29.96	61.55
Tangible Book Value, 5 Yr. CAGR %	-	121.66	83.94	27.46	62.44
Common Equity, 5 Yr. CAGR %	-	121.66	83.94	27.46	62.44
Cash From Operations, 5 Yr. CAGR %	-	74.55	64.79	53.59	37.26
Capital Expenditures, 5 Yr. CAGR %	-	18.07	40.36	34.65	50.86
Levered Free Cash Flow, 5 Yr. CAGR %	-	-	59.64	53.38	35.92
Unlevered Free Cash Flow, 5 Yr. CAGR %	-	-	59.64	53.38	35.92